Companies › Shenzhen Celconta Life Science
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PANK-003 cell injection Peripheral blood-derived allogeneic natural killer cells | – | Phase 1 | Solid Tumors, Adult | Jan 2027 |
| XKDCT225 anti-CLDN18.2 CAR-T cell therapy | – | Phase 1 | Claudin18.2 Positive Advanced Solid Tumors | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06897228 | PANK-003 cell injection | Phase 1 | Solid Tumors, Adult | Oncology | Jan 2027 |
| NCT06782425 | XKDCT225 | Phase 1 | Claudin18.2 Positive Advanced Solid Tumors | Oncology | Jan 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.